WO1997045138A1 - New improved formulation for treatment of thromboembolism - Google Patents

New improved formulation for treatment of thromboembolism Download PDF

Info

Publication number
WO1997045138A1
WO1997045138A1 PCT/SE1997/000914 SE9700914W WO9745138A1 WO 1997045138 A1 WO1997045138 A1 WO 1997045138A1 SE 9700914 W SE9700914 W SE 9700914W WO 9745138 A1 WO9745138 A1 WO 9745138A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical formulation
carbon atoms
enhancing agent
formulation according
absoφtion enhancing
Prior art date
Application number
PCT/SE1997/000914
Other languages
French (fr)
Inventor
Jan-Erik Löfroth
Lennart Lindfors
Anna-Lena Ungell
Original Assignee
Astra Aktiebolag (Publ)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Aktiebolag (Publ) filed Critical Astra Aktiebolag (Publ)
Priority to NZ332788A priority Critical patent/NZ332788A/en
Priority to DE69731981T priority patent/DE69731981T2/en
Priority to EP97926326A priority patent/EP1015022B1/en
Priority to JP09542227A priority patent/JP2000511526A/en
Priority to CA002253410A priority patent/CA2253410A1/en
Priority to AU31115/97A priority patent/AU722450B2/en
Priority to US08/894,615 priority patent/US6673365B1/en
Priority to AT97926326T priority patent/ATE284706T1/en
Publication of WO1997045138A1 publication Critical patent/WO1997045138A1/en
Priority to NO985558A priority patent/NO985558D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to a new pharmaceutical formulation comprising the thrombin inhibitor HOOC-CH2-(R)-Cgl-Aze-Pab in combination with one or more absorption enhancing medium chain glyceride lipid agents, a process for the preparation of such a pharmaceutical formulation, the use of the thrombin inhibitor and the absorption enhancing agent for the preparation of a pharmaceutical formulation for the treatment of thromboembolism as well as a method of treating a patient in need of such a treatment by using said formulation.
  • Blood coagulation is the key process involved in both haemostasis (i.e. prevention of blood loss from a damaged vessel) and thrombosis (i.e. the pathological occlusion of a blood vessel by a blood clot).
  • Coagulation is the result of a complex series of enzymatic reactions, where one of the final steps is conversion of the proenzyme prothrombin to the active enzyme thrombin.
  • Thrombin plays a central role in coagulation. It activates platelets, it converts fibrinogen into fibrin monomers, which polymerise spontaneously into filaments, and it activates factor XL ⁇ , which in turn crosslinks the polymer to insoluble fibrin. Thrombin further activates factor V and factor VIII in a positive feedback reaction. Inhibitors of thrombin are therefore expected to be effective anticoagulants by inhibition of platelets, fibrin formation and fibrin stabilization. By inhibiting the positive feedback mechanism they are expected to excert inhibition early in the chain of events leading to coagulation and thrombosis.
  • Peptidic or peptidic like thrombin inhibitors as many other peptide like substances are prone to limited or variable absorption when administered orally. This is due to the influence from different barriers of metabolic and physical character, like enzymatic degradation, tendencies of complex formation with components from the formulation or the biological environment, limitations in transport over the intestinal membranes etc.
  • One object of the pharmaceutical formulation is to facilitate the active agent in overcoming such barriers, and to obtain an enhanced and reproduceable abso ⁇ tion of the active agent.
  • Formulation components that have such influence and thus can help the active agent are called abso ⁇ tion enhancers.
  • the main interest has been to utilize mixtures of mono-, di-, and triglycerides with 6 - 12 carbon atoms in the chains, i e mono-, di-, and triacylglycerides. More or less well defined samples of glycerides have been used, e g glyceryl mono-octanoate (Tramedico), Capmul MCM (Karlshamns Lipidteknik), Nikkol MGK (Nikko Chemicals), SunSoft (Taiyo Kagaku), Imwitor (Huls), Labrasol (Gattefosse), LAS (Gattefosse), and Labrafac Lipo (Gattefosse).
  • an object of the present invention is to provide novel pharmaceutical formulations comprising the thrombin inhibitor HOOC-CH2-(R)-Cgl-Aze-Pab in combination with one or more medium chain glyceride lipid agents, and a process for the preparation of such pharmaceutical formulations.
  • the improved formulations of this therapeutically active drug are based on the use of medium chain glycerides to obtain positive synergistic effects which result in an enhanced and/or less variable abso ⁇ tion when the therapeutically active agent is given by different administration routes, such as the oral, the rectal, the buccal, the nasal or the pulmonary route etc.
  • the formulation may be manufactured with the active peptidic thrombin inhibitor HOOC- CH2-(R)-Cgl-Aze-Pab as commonly used salt or in its base form.
  • the thrombin inhibitor may also be in other stereoisomeric configurations than the one above.
  • novel pharmaceutical formulations disclosed in this invention are unique combinations of the thrombin inhibitor HOOC-CH2-(R)-Cgl-Aze-Pab and the medium chain glyceride lipid agents as enhancing agents.
  • glycerides from different sources behave differently, the most effecient enhancing effect being obtained with the pure glyceryl mono-octanoate (1- monocaprylin).
  • the enhancing effects are considered to be due to combinations of several interactions, both between the glycerides and the gastro-intestinal membranes, and between the glycerides and the thrombin inhibitor.
  • the (water-soluble) thrombin inhibitor is soluble in such glycerides without the use of (extra-added) water.
  • phase diagram displayed by, e g the glyceryl monooctanoate in water shows that a fluid isotropic phase (L2) is formed at a low water content.
  • L2 fluid isotropic phase
  • These inverted micelles will then provide aggregates with the thrombin inhibitor ready for abso ⁇ tion, the abso ⁇ tion events being enhanced by the presence of the fusogenic lipids.
  • phase diagrams of longer medium chain glycerides, e g 1-monocaprin it can be concluded that the higher temperature needed to obtain a fluid isotropic phase at low water content would make it more difficult for such glycerides to act as enhancers.
  • the formulations disclosed here are based on the use of medium chain glycerides, and mixtures thereof, without the requirements of dispersing the lipids with other agents such as emulsifiers for producing microemulsions, lecithins to provide self-emulsifying systems, or any other similar agent. Further, it is worth to emphazise that no water is needed in the formulation according to the invention.
  • Rl, R2 and R3 are the same or different and each represent an hydrogen atom or acyl group having 6 - 12 carbon atoms provided that at least one of Rl, R2 and R3 is an acyl group.
  • the dosage form used may be a solid, semisolid or liquid preparations prepared by per se known techniques. Usually the active substance will constitute between 0.1 and 99 % by weight of the preparation. Suitable daily doses of the therapeutically active drug in therapeutical treatment of humans are about 0.001 - 100 mg/kg body weight at peroral administration.
  • the enhancing agent or combinations of enhancing agents, will constitute between 0.1 and 99 % by weight of the preparation.
  • the formulations thus obtained will increase the abso ⁇ tion and/or minimize the variability of the abso ⁇ tion of the therapeutically active drug by different mechanisms.
  • compositions of the present invention comprising the modified dipeptide HOOC-CH2-(R)-Cgl-Aze-Pab and the abso ⁇ tion enhancing agent are intended for prophylaxis and treatment in arterial as well as venous thromboembolism.
  • Formulation A HOOC-CH 2 -(R)-Cgl-Aze-Pab (base) 0.43 mg/ml
  • 1 ml of formulation contains 0.9 g of akoline + 0.1 g of buffer + 0.43 g of drug.
  • Akoline was heated to 30°C and was mixed with the buffer containing the thrombin inhibitor HOOC-CH2-(R)-Cgl-Aze-Pab in the proportion of akoline: water 90:10.
  • Formulation B HOOC-CH 2 -(R)-Cgl-Aze-Pab (base) 0.43 mg/ml
  • 1 ml of formulation contains 1 g of akoline + 0.43 g of drug.
  • Akohne was heated to 30°C and was mixed with the thrombin inhibitor HOOC-CH2-(R)- Cgl-Aze-Pab (base).
  • Formulation C HOOC-CH 2 -(R)-Cgl-Aze-Pab (base) 0.43 mg/ml Monoglyceride C8:0 Monoglyceride C10:0 Phosphate buffer 0.1 M, pH 8.0
  • 1 ml of formulation contains 0.7 g of C8:0 + 0.26 g of C10:0 + 0.04 g of buffer + 0.43 g of drug.
  • Monoglyceride C8:0 was heated to 35°C and the monoglyceride C10:0 was heated to 70°C.
  • the mono-C10:0 was added to the mono-C8:0 in the proportions 26:70 respectively and the buffer solution containing the thrombin inhibitor HOOC-CH2-(R)-Cgl-Aze-Pab was added into the mixture to a total of 4%. The mixture was then shaken and kept warm (30°C) before administration.
  • 1 ml of formulation contains 0.95 g of C8:0 + 0.05 g of buffer + 0.43 g of drug.
  • Monoglyceride C8:0 was heated to 30°C and the thrombin inhibitor HOOC-CH2-(R)-Cgl- Aze-Pab in phosphate buffer was added to the mixture to a total amount of 5%. The mixture was then shaken before administration.
  • the formulations, A to D, respectively, were tested in vivo in the rat model using intraduodenally catheterised non-anaesthetised animals. Formulations were given as a bolus. Blood samples were withdrawn at certain time points for up to 4 hours after administration of the different formulation. The concentration of HOOC-CH2-(R)-Cgl-Aze-Pab were analysed in the plasma and the bioavailability calculated from the Area under the curve (AUC) using standard pharmacokinetic methods (Rowland and Tozer, Clinical Pharmacokinetics, concepts and applications, 1980).
  • Pab l-Amidino-4-aminomethyl benzene Table 1. Bioavailability of HOOC-CH2-(R)-Cgl-Aze-Pab in vivo in the rat after administration intraduodenally with formulations containing monoglycerides or mono- and diglyceride mixtures described in the invention. Numbers represent the mean values +- SD, where N indicates the number of animal used.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A new pharmaceutical formulation comprising the thrombin inhibitor HOOC-CH2-(R)-Cgl-Aze-Pab in combination with medium chain glycerides, a process for the preparation of such a pharmaceutical formulation, the use of such formulation in the treatment of thromboembolism as well as a method of treating a patient in need of such a treatment by using said formulation.

Description

NEW IMPROVED FORMULATION FOR TREATMENT OF THROMBOEMBOLISM
Field of the invention
The present invention relates to a new pharmaceutical formulation comprising the thrombin inhibitor HOOC-CH2-(R)-Cgl-Aze-Pab in combination with one or more absorption enhancing medium chain glyceride lipid agents, a process for the preparation of such a pharmaceutical formulation, the use of the thrombin inhibitor and the absorption enhancing agent for the preparation of a pharmaceutical formulation for the treatment of thromboembolism as well as a method of treating a patient in need of such a treatment by using said formulation.
Background
Blood coagulation is the key process involved in both haemostasis (i.e. prevention of blood loss from a damaged vessel) and thrombosis (i.e. the pathological occlusion of a blood vessel by a blood clot). Coagulation is the result of a complex series of enzymatic reactions, where one of the final steps is conversion of the proenzyme prothrombin to the active enzyme thrombin.
Thrombin plays a central role in coagulation. It activates platelets, it converts fibrinogen into fibrin monomers, which polymerise spontaneously into filaments, and it activates factor XLπ, which in turn crosslinks the polymer to insoluble fibrin. Thrombin further activates factor V and factor VIII in a positive feedback reaction. Inhibitors of thrombin are therefore expected to be effective anticoagulants by inhibition of platelets, fibrin formation and fibrin stabilization. By inhibiting the positive feedback mechanism they are expected to excert inhibition early in the chain of events leading to coagulation and thrombosis.
Peptidic or peptidic like thrombin inhibitors as many other peptide like substances, are prone to limited or variable absorption when administered orally. This is due to the influence from different barriers of metabolic and physical character, like enzymatic degradation, tendencies of complex formation with components from the formulation or the biological environment, limitations in transport over the intestinal membranes etc. One object of the pharmaceutical formulation is to facilitate the active agent in overcoming such barriers, and to obtain an enhanced and reproduceable absoφtion of the active agent. Formulation components that have such influence and thus can help the active agent are called absoφtion enhancers.
Prior Art
Concerning the use of absoφtion enhancers of lipidic origin in pharmaceutical formulations, several reports and reviews in the literature exist. Comprehensive reviews have been presented by E J van Hoogdalem et al., Pharmac Theor vol 44, 407-443 (1989), by S Muranishi, Crit Rev Ther Drug Carrier Syst vol 7, 1-33 (1990), by E S Swenson and W J Curatolo, Adv Drug Deliv Rev vol 8, 39-92 (1992), and in drug Absoφtion Enhancement (Ed.: A B G de Boer), Harwood Academic Publishers 1994. Specifically, medium chain glycerides have been studied and reported as absoφtion enhancers in a number of papers, see references above and references therein. The main interest has been to utilize mixtures of mono-, di-, and triglycerides with 6 - 12 carbon atoms in the chains, i e mono-, di-, and triacylglycerides. More or less well defined samples of glycerides have been used, e g glyceryl mono-octanoate (Tramedico), Capmul MCM (Karlshamns Lipidteknik), Nikkol MGK (Nikko Chemicals), SunSoft (Taiyo Kagaku), Imwitor (Huls), Labrasol (Gattefosse), LAS (Gattefosse), and Labrafac Lipo (Gattefosse). Only a few reports deal with effects obtained when the glycerides have been perorally administered (Sekine et al. J Pharmacobio-Dyn 8, 286 ( 1985); Beskid et al. Chemotherapy 34, 77 ( 1988)). Several other studies report results when liquid formulations of the glycerides have been administered rectally (Sekine et al. J Pharmacobio-Dyn 7, 856 (1984); ibid 8, 633, 645, and 653 (1985); van Hoogdalem et al. J Pharm Pharmacol 40, 329 (1988), Pharm Res 5, 453 (1988); Unowsky et al. Chemotherapy 34, 272 (1988); Watanabe et al. J Pharm Sci 77, 847 (1988); Matsumoto et al. Chem Pharm Bull 37, 2477 (1989)), or directly as solutions or emulsions by infusion or bolus into different parts of the small intestine (Petty et al. at "Interci Conf on Antimicrobial Agents and Chemotherapy", New Orleans 1986, abstract 1245; Higaki et al. J Pharmacobio-Dyn 9, 532 (1986), Int J Pharm 36, 131 (1987); Yeh et al. Proceed Intern Symp Control Rel Bioact Mater (CRS), 20, 176 (1993); Constantinides et al. CRS 20, 184 (1993); CRS 21, 62 (1994); Marks et al. CRS 22 (1995); Yeh et al. Pharm Res 11, 1 148 (1994); Constantinides et al. Pharm Res 11, 1385 (1994), J Controlled Release 34, 109 (1995); Yeh et al. J Controlled Release 36, 109 (1995); Constantinides et al. Pharm Res 12, 1561 (1995)). The glycerides were used either as such, or in mixtures with dispersing agents like lecithins and surfactants to form aggregates like mixed micelles, microemulsions, dispersed lamellar phases etc, or to form self-emulsifying systems. A few patents have also claimed the use of such glycerides in formulations, e g as components in microemulsions (Constantinides WO 94/19003 and references therein), and in selfemulsifying systems with lecithins (Herslδf WO 92/05771 and references therein).
Disclosure of the invention
It has been found that the absoφtion of the thrombin inhibitor HOOC-CH2-(R)-Cgl-Aze- Pab (disclosed in EP 701 568) can be modified beneficially by incoφorating medium chain glyceride lipid agent in the pharmaceutical formulations containing said therapeutically active compound.
Therefore, an object of the present invention is to provide novel pharmaceutical formulations comprising the thrombin inhibitor HOOC-CH2-(R)-Cgl-Aze-Pab in combination with one or more medium chain glyceride lipid agents, and a process for the preparation of such pharmaceutical formulations.
The improved formulations of this therapeutically active drug are based on the use of medium chain glycerides to obtain positive synergistic effects which result in an enhanced and/or less variable absoφtion when the therapeutically active agent is given by different administration routes, such as the oral, the rectal, the buccal, the nasal or the pulmonary route etc.
The formulation may be manufactured with the active peptidic thrombin inhibitor HOOC- CH2-(R)-Cgl-Aze-Pab as commonly used salt or in its base form. The thrombin inhibitor may also be in other stereoisomeric configurations than the one above.
The novel pharmaceutical formulations disclosed in this invention are unique combinations of the thrombin inhibitor HOOC-CH2-(R)-Cgl-Aze-Pab and the medium chain glyceride lipid agents as enhancing agents.
Thus, first the use of these absoφtion enhancing agents in combinations with thrombin inhibitors have not presented before.
Second, it has been found that glycerides from different sources behave differently, the most effecient enhancing effect being obtained with the pure glyceryl mono-octanoate (1- monocaprylin). Tentatively, the enhancing effects are considered to be due to combinations of several interactions, both between the glycerides and the gastro-intestinal membranes, and between the glycerides and the thrombin inhibitor. Thus, the (water-soluble) thrombin inhibitor is soluble in such glycerides without the use of (extra-added) water. Also, the phase diagram displayed by, e g the glyceryl monooctanoate in water (Larsson, Zeitschrift Phys Chem Neue Folge 56, 173 - 198 (1967), shows that a fluid isotropic phase (L2) is formed at a low water content. These inverted micelles will then provide aggregates with the thrombin inhibitor ready for absoφtion, the absoφtion events being enhanced by the presence of the fusogenic lipids. From the phase diagrams of longer medium chain glycerides, e g 1-monocaprin, it can be concluded that the higher temperature needed to obtain a fluid isotropic phase at low water content would make it more difficult for such glycerides to act as enhancers. Third, it has been found in experiments with different species (rat, dog, human) that a substantial enhancing effect is observed only when the thrombin inhibitor together with the medium chain glyceride lipid agents are administered directly to the small intestine, that is intraduodenal administration by the use of a duodenal tube, Hg - or tungsten - weighted tube or an endoscopy tube or by enteric coated formulations. On the other hand, direct administration to either the stomach or the colon results in negligable enhancing effects. This is in shaφ contrast to most other reports on enhancing effects from medium chain glycerides.
Fourth, the formulations disclosed here are based on the use of medium chain glycerides, and mixtures thereof, without the requirements of dispersing the lipids with other agents such as emulsifiers for producing microemulsions, lecithins to provide self-emulsifying systems, or any other similar agent. Further, it is worth to emphazise that no water is needed in the formulation according to the invention.
Medium chain glycerides according to the present invention is defined as compounds of the formula
ChL-O-R,
I
CH-0-R2
I
CH2-0-R3
wherein Rl, R2 and R3 are the same or different and each represent an hydrogen atom or acyl group having 6 - 12 carbon atoms provided that at least one of Rl, R2 and R3 is an acyl group.
The dosage form used may be a solid, semisolid or liquid preparations prepared by per se known techniques. Usually the active substance will constitute between 0.1 and 99 % by weight of the preparation. Suitable daily doses of the therapeutically active drug in therapeutical treatment of humans are about 0.001 - 100 mg/kg body weight at peroral administration.
The enhancing agent, or combinations of enhancing agents, will constitute between 0.1 and 99 % by weight of the preparation. The formulations thus obtained will increase the absoφtion and/or minimize the variability of the absoφtion of the therapeutically active drug by different mechanisms.
The pharmaceutical formulations of the present invention comprising the modified dipeptide HOOC-CH2-(R)-Cgl-Aze-Pab and the absoφtion enhancing agent are intended for prophylaxis and treatment in arterial as well as venous thromboembolism.
Detailed description of the invention
The following description is illustrative of aspects of the invention.
Experimental part
Preparation of the formulations
Formulation A: HOOC-CH2-(R)-Cgl-Aze-Pab (base) 0.43 mg/ml Akoline (Capmul MCM) Phosphate buffer 0.1 M , pH 8.0
1 ml of formulation contains 0.9 g of akoline + 0.1 g of buffer + 0.43 g of drug. Akoline was heated to 30°C and was mixed with the buffer containing the thrombin inhibitor HOOC-CH2-(R)-Cgl-Aze-Pab in the proportion of akoline: water 90:10. Formulation B: HOOC-CH2-(R)-Cgl-Aze-Pab (base) 0.43 mg/ml Akoline (Capmul MCM)
1 ml of formulation contains 1 g of akoline + 0.43 g of drug. Akohne was heated to 30°C and was mixed with the thrombin inhibitor HOOC-CH2-(R)- Cgl-Aze-Pab (base).
Formulation C: HOOC-CH2-(R)-Cgl-Aze-Pab (base) 0.43 mg/ml Monoglyceride C8:0 Monoglyceride C10:0 Phosphate buffer 0.1 M, pH 8.0
1 ml of formulation contains 0.7 g of C8:0 + 0.26 g of C10:0 + 0.04 g of buffer + 0.43 g of drug. Monoglyceride C8:0 was heated to 35°C and the monoglyceride C10:0 was heated to 70°C. The mono-C10:0 was added to the mono-C8:0 in the proportions 26:70 respectively and the buffer solution containing the thrombin inhibitor HOOC-CH2-(R)-Cgl-Aze-Pab was added into the mixture to a total of 4%. The mixture was then shaken and kept warm (30°C) before administration.
Formulation D: HOOC-CH2-(R)-Cgl-Aze-Pab (base) 0.43 mg/ml Monoglyceride C8:0
Phosphate buffer 0.1 M, pH 8.0
1 ml of formulation contains 0.95 g of C8:0 + 0.05 g of buffer + 0.43 g of drug. Monoglyceride C8:0 was heated to 30°C and the thrombin inhibitor HOOC-CH2-(R)-Cgl- Aze-Pab in phosphate buffer was added to the mixture to a total amount of 5%. The mixture was then shaken before administration.
The formulations, A to D, respectively, were tested in vivo in the rat model using intraduodenally catheterised non-anaesthetised animals. Formulations were given as a bolus. Blood samples were withdrawn at certain time points for up to 4 hours after administration of the different formulation. The concentration of HOOC-CH2-(R)-Cgl-Aze-Pab were analysed in the plasma and the bioavailability calculated from the Area under the curve (AUC) using standard pharmacokinetic methods (Rowland and Tozer, Clinical Pharmacokinetics, concepts and applications, 1980).
The results from the tested formulations A to D in vivo in the rat are presented in Table 1 as formulations 2-5. The bioavailability increase between tenfold to twentyfold using the different formulations mentioned in the invention as compared to control experiment where only phosphate buffer of pH 8 was used (1). Formulation B was also tested in human healthy subjects using enteric coated capsules for administration directly to the duodenum. The results from the human study also indicate a tenfold increased absoφtion as compared to a control tablet or solution of the thrombin inhibitor base only.
All formulations tested containing the mono and / or di glycerides C8 and CIO increased the bioavailability of the thrombin inhibitor HOOC-CH2-(R)-Cgl-Aze-Pab suφrisingly well from the upper GI tract.
Abbreviations
Aze = (S) -Azetidine-2-carboxylic acid
Cgl = (S) -Cyclohexyl glycine
Pab = l-Amidino-4-aminomethyl benzene Table 1. Bioavailability of HOOC-CH2-(R)-Cgl-Aze-Pab in vivo in the rat after administration intraduodenally with formulations containing monoglycerides or mono- and diglyceride mixtures described in the invention. Numbers represent the mean values +- SD, where N indicates the number of animal used.
Formulation Bioavailability (%) mean SD N
1. Phosphate buffer 0.1 M, pH 8.0 3.0 2.5 4
2. Capmul:water 90:10 37.2 9.2 4
3. Capmul 100% 55.5 14.6 4
4. Mono- C8/C10 : water 96:4 47.8 8.6 3
5. Mono C8 :water 95:5 73 5.1 3

Claims

1. A pharmaceutical formulation comprising the therapeutically active compound HOOC- CH2-(R)CgI-Aze-Pab or a physiologically acceptable salt thereof and one or more absoφtion enhancing agents selected from the group of a mono-, di- or triglyceride comprising at least one acyl group of chain length of 6 to 12 carbon atoms.
2. A pharmaceutical formulation according to claim 1 wherein the acyl group contains 8 to 10 carbon atoms.
3. A pharmaceutical formulation according to claim 1 wherein the absoφtion enhancing agent is selected from mixtures of mono-, di- or triglycerides with acyl groups containing 8 carbon atoms.
4. A pharmaceutical formulation according to claim 1 wherein the absoφtion enhancing agents is selected from mixtures of mono- or diglycerides having acyl groups of 6 to 12 carbon atoms.
5. A pharmaceutical formulation according to claim 1 wherein the absoφtion enhancing agent is selected from mixtures of mono- or diglycerides having acyl groups of 8 to 10 carbon atoms.
6. A pharmaceutical formulation according to claim 1 wherein the absoφtion enhancing agent is selected from mixtures of mono- or diglycerides having acyl groups of 8 carbon atoms.
7. A pharmaceutical formulation according to claim 1 wherein the absoφtion enhancing agent is selected from mixtures of monoglycerides having acyl groups of 6 to 12 carbon atoms.
8. A pharmaceutical formulation according to claim 1 wherein the absoφtion enhancing agent is selected from mixtures of monoglycerides having acyl groups of 8 to 10 carbon atoms.
9. A pharmaceutical formulation according to claim 1 wherein the absoφtion enhancing agent is a monoglyceride having its acyl group of 6 carbon atoms.
10. A pharmaceutical formulation according to claim 1 wherein the absoφtion enhancing agent is a monoglyceride having its acyl group of 8 carbon atoms.
1 1. A pharmaceutical formulation according to claim 1 wherein the absoφtion enhancing agent is a monoglyceride having its acyl group of 10 carbon atoms.
12. A pharmaceutical formulation according to claim 1 wherein the absoφtion enhancing agent is a monoglyceride having its acyl group of 12 carbon atoms.
13. A pharmaceutical formulation according to claim 1 wherein the absoφtion enhancing agent is selected from mixtures of diglycerides having acyl groups of 6 to 12 carbon atoms.
14. A pharmaceutical formulation according to claim 1 wherein the absoφtion enhancing agent is selected from mixtures of diglycerides having acyl groups of 8 to 10 carbon atoms.
15. A pharmaceutical formulation according to claim 1 wherein the absoφtion enhancing agent is a diglyceride having acyl groups of 6 carbon atoms.
16. A pharmaceutical formulation according to claim 1 wherein the absoφtion enhancing agent is a diglyceride having acyl groups of 8 carbon atoms.
17. A pharmaceutical formulation according to claim 1 wherein the absoφtion enhancing agent is a diglyceride having acyl groups of 10 carbon atoms.
18. A pharmaceutical formulation according to claim 1 wherein the absoφtion enhancing agent is a diglyceride having acyl groups of 12 carbon atoms.
19. A mixture comprising the therapeutically active compound HOOC-CH2-(R)Cgl-Aze- Pab or a physiologically acceptable salt thereof and one or more absoφtion enhancing agents selected from the group of a mono-, di- or triglyceride comprising at least one acyl group of chain length of 6 to 12 carbon atoms.
20. Use of the thrombin inhibitor and the absoφtion enhancing agent as defined in any of the preceding claims 1 to 19 for the preparation of a pharmaceutical formulation for the treatment of thromboembolism by administration directly to the small intestine.
21. Use according to claim 20 wherein the formulation is adapted for the administration by a duodenal tube, a mercury or tungsten weighted tube or an endoscopy tube.
22. Use according to claim 20 or claim 21 wherein the formulation is enteric coated.
23. A method of treating a patient in need of antithrombolic treatment comprising administering to said patient a pharmaceutical formulation as defined in any one of the claims 1 to 19 by administration directly to the small intestine.
24. A method according to claim 23 wherein the administration is by use of a duodenal tube, mercury or tungsten weighted tube or an endoscopy tube.
25. A method according to claim 23 or claim 24 wherein the formulation is enteric coated.
26. A pharmaceutical formulation according to claim 1 wherein the absoφtion enhancing agent forms micelles which provides aggregates with the thrombin inhibitor.
PCT/SE1997/000914 1996-05-31 1997-05-28 New improved formulation for treatment of thromboembolism WO1997045138A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
NZ332788A NZ332788A (en) 1996-05-31 1997-05-28 Composition for the treatment of thromboebolism
DE69731981T DE69731981T2 (en) 1996-05-31 1997-05-28 NEW IMPROVED FORMULATION FOR THE TREATMENT OF THROMBOEMBOLISM
EP97926326A EP1015022B1 (en) 1996-05-31 1997-05-28 New improved formulation for treatment of thromboembolism
JP09542227A JP2000511526A (en) 1996-05-31 1997-05-28 Novel improved compositions for the treatment of thrombosis
CA002253410A CA2253410A1 (en) 1996-05-31 1997-05-28 New improved formulation for treatment of thromboembolism
AU31115/97A AU722450B2 (en) 1996-05-31 1997-05-28 New improved formulation for treatment of thromboembolism
US08/894,615 US6673365B1 (en) 1996-05-31 1997-05-28 Formulation for treatment of thromboembolism
AT97926326T ATE284706T1 (en) 1996-05-31 1997-05-28 NEW IMPROVED FORMULATION FOR THE TREATMENT OF THROMBOEMBOLISM
NO985558A NO985558D0 (en) 1996-05-31 1998-11-27 New improved formulation for the treatment of thromboembolism

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9602145A SE9602145D0 (en) 1996-05-31 1996-05-31 New improved formulation for the treatment of thromboembolism
SE9602145-6 1996-05-31

Publications (1)

Publication Number Publication Date
WO1997045138A1 true WO1997045138A1 (en) 1997-12-04

Family

ID=20402816

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1997/000914 WO1997045138A1 (en) 1996-05-31 1997-05-28 New improved formulation for treatment of thromboembolism

Country Status (14)

Country Link
US (1) US6673365B1 (en)
EP (1) EP1015022B1 (en)
JP (1) JP2000511526A (en)
AR (1) AR013569A1 (en)
AT (1) ATE284706T1 (en)
AU (1) AU722450B2 (en)
CA (1) CA2253410A1 (en)
DE (1) DE69731981T2 (en)
ID (1) ID19472A (en)
NO (1) NO985558D0 (en)
NZ (1) NZ332788A (en)
SE (1) SE9602145D0 (en)
WO (1) WO1997045138A1 (en)
ZA (1) ZA974386B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
WO2004043486A1 (en) * 2002-11-12 2004-05-27 Astrazeneca Ab An acqueous pharmaceutical formulation comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture of a medicament for use by nasal administration in treating thromboembolism
EP2982668A2 (en) 2002-12-03 2016-02-10 Pharmacyclics LLC 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors for the treatment of thromboembolic disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007472A1 (en) * 1992-10-02 1994-04-14 Pfizer Inc. Pharmaceutical compositions containing nonionic surfactants
WO1994029336A1 (en) * 1993-06-03 1994-12-22 Astra Aktiebolag New peptide derivatives
WO1995000152A1 (en) * 1993-06-18 1995-01-05 Pharmacia Ab Pharmaceutical composition containing heparin, heparin fragments or their derivatives in combination with glycerol esters
WO1996016671A1 (en) * 1994-12-02 1996-06-06 Astra Aktiebolag New antithrombotic formulation, process for its manufacturing, and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464175A (en) * 1982-08-25 1984-08-07 Altman Alan R Multipurpose tamponade and thrombosclerotherapy tube
US4568545A (en) * 1982-10-02 1986-02-04 Amano Seiyaku Kabushiki Kaisha Thrombolytic agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007472A1 (en) * 1992-10-02 1994-04-14 Pfizer Inc. Pharmaceutical compositions containing nonionic surfactants
WO1994029336A1 (en) * 1993-06-03 1994-12-22 Astra Aktiebolag New peptide derivatives
WO1995000152A1 (en) * 1993-06-18 1995-01-05 Pharmacia Ab Pharmaceutical composition containing heparin, heparin fragments or their derivatives in combination with glycerol esters
WO1996016671A1 (en) * 1994-12-02 1996-06-06 Astra Aktiebolag New antithrombotic formulation, process for its manufacturing, and use thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
WO2004043486A1 (en) * 2002-11-12 2004-05-27 Astrazeneca Ab An acqueous pharmaceutical formulation comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture of a medicament for use by nasal administration in treating thromboembolism
EP2982668A2 (en) 2002-12-03 2016-02-10 Pharmacyclics LLC 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors for the treatment of thromboembolic disorders

Also Published As

Publication number Publication date
ATE284706T1 (en) 2005-01-15
NO985558L (en) 1998-11-27
DE69731981D1 (en) 2005-01-20
NZ332788A (en) 2000-05-26
EP1015022A1 (en) 2000-07-05
ID19472A (en) 1998-07-16
CA2253410A1 (en) 1997-12-04
EP1015022B1 (en) 2004-12-15
NO985558D0 (en) 1998-11-27
AR013569A1 (en) 2001-01-10
SE9602145D0 (en) 1996-05-31
JP2000511526A (en) 2000-09-05
DE69731981T2 (en) 2005-12-22
AU3111597A (en) 1998-01-05
ZA974386B (en) 1997-12-01
US6673365B1 (en) 2004-01-06
AU722450B2 (en) 2000-08-03

Similar Documents

Publication Publication Date Title
KR100498646B1 (en) Oral Peptide Pharmaceutical Compositions
JP3487860B2 (en) Controlled release composition forming reverse micelle (L2) structure or normal micelle (L1) structure
EP0143949B1 (en) Pharmaceutical composition containing urokinase
CA2446619C (en) Permeation enhancers
JPH09510182A (en) Encapsulated transparent liquid for drug delivery
PT100400B (en) MICROEMULATIONS FORMULATIONS CONVERTIVEIS
JP2005508938A (en) Promicelle pharmaceutical composition
JPS60248618A (en) Dipeptide-containing remedy for ulcer
JPH08502492A (en) Therapeutic microemulsion
EP0287036A2 (en) New pharmaceutical compositions comprising esters or amides as active ingredients
DE69717067T2 (en) A pharmaceutical preparation comprising coated capsules or tablets containing liposome powder containing an active ingredient
Rózsa et al. Evidence for a role of capsaicin-sensitive mucosal afferent nerves in the regulation of mesenteric blood flow in the dog
JPS6051106A (en) Long acting pharmaceutical preparation of amosulalol hydrochloride
RU2203649C2 (en) New liposome vectors of active substances
Ribet et al. Use of caerulein with submaximal doses of secretin as a test of pancreatic function in man.
AU722450B2 (en) New improved formulation for treatment of thromboembolism
JPH06192107A (en) Glycyrrhizin oral agent
JPH08504759A (en) Invertable microemulsion composition
JPS5910524A (en) Interferon composition and its preparation
JPS63406B2 (en)
US20240277682A1 (en) Pharmaceutical hydronidone formulations for diseases
JPS6213927B2 (en)
JP2938579B2 (en) GI wall protectant
Kiriyama et al. The bioavailability of oral dosage forms of a new HIV‐1 protease inhibitor, KNI‐272, in beagle dogs
KR100402037B1 (en) Enteric-soluble drug of beta-galactosidase

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 08894615

Country of ref document: US

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997926326

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2253410

Country of ref document: CA

Ref country code: CA

Ref document number: 2253410

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 332788

Country of ref document: NZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997926326

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1997926326

Country of ref document: EP